Individualized Obesity Pharmacotherapy

NCT03374956 on ClinicalTrials.gov · last registry update 2023-07-18

A small phase 3 — 193 participants, against a typical 424. The sponsor logged completion for 26 May 2022. Primary outcome, as filed: Change in Total Body Weight. liraglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P3
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Mayo Clinic
Sponsor type: Other
Enrollment: 193
Started: 2017-12-11
Primary completion: 2022-05-26 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in Total Body Weight

Conditions studied

Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.